natgillin/translations-raw huggingface dataset:
For products that may lead to residues in food or feed, the need to set new or to amend existing maximum residue levels (MRLs) in accordance with Regulation (EC) No 470/2009 of the European Parliament and of the Council [3] or Regulation (EC) No 396/2005 of the European Parliament and of the Council [4] shall be verified, and any appropriate risk mitigation measures shall be taken to ensure that the applicable MRLs are not exceeded.
Za proizvode koji mogu dovesti do ostataka u hrani ili hrani za životinje, potrebu za određivanjem novih ili izmjenom i dopunom postojećih maksimalnih razina ostataka (MRO), u skladu s Uredbom (EZ) br. 470/2009 Europskog parlamenta i Vijeća [3] ili Uredbom (EZ) br. 396/2005 Europskog parlamenta i Vijeća [4] treba provjeriti i poduzeti odgovarajuće mjere za smanjenje rizika kako bi se osiguralo da se ne prijeđu važeći MRO-i.
For products that may lead to residues in food or feed, the need to set new or to amend existing maximum residue levels (MRLs) in accordance with Regulation (EC) No 470/2009 or Regulation (EC) No 396/2005 shall be verified, and any appropriate risk mitigation measures shall be taken to ensure that the applicable MRLs are not exceeded.
Za proizvode koji mogu dovesti do ostataka u hrani ili hrani za životinje, potrebu za određivanjem novih ili izmjenom i dopunom postojećih maksimalnih razina ostataka (MRO), u skladu s Uredbom (EZ) br. 470/2009 Europskog parlamenta i Vijeća ili Uredbom (EZ) br. 396/2005 Europskog parlamenta i Vijeća, treba provjeriti i poduzeti odgovarajuće mjere za smanjenje rizika kako bi se osiguralo da se ne prijeđu važeći MRO-i.
Products containing benzoic acid shall not be incorporated in materials and articles intended to come into contact with food within the meaning of Article 1(1) of Regulation (EC) No 1935/2004, unless the Commission has established specific limits on the migration of benzoic acid into food or it has been established pursuant to that Regulation that such limits are not necessary.
Proizvodi koji sadrže benzojevu kiselinu neće se uključiti u materijale i predmete koji, izravno ili neizravno, dolaze u dodir s hranom u smislu članka 1. stavka 1. Uredbe (EZ) br. 1935/2004, osim ako Komisija odredi specifična ograničenja migracije benzojeve kiseline u hranu ili se tom Uredbom odredi da takva ograničenja nisu potrebna.
Commission Implementing Regulation (EU) No 1036/2013
Provedbena uredba Komisije (EU) br. 1036/2013
approving etofenprox as an existing active substance for use in biocidal products for product-type 18
o odobrenje etofenproksa kao postojeće aktivne tvari za uporabu u biocidnim pripravcima za vrstu proizvoda 18
Commission Regulation (EC) No 1451/2007 [2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council [3].
Uredbom Komisije (EZ) br. 1451/2007 [2] utvrđen je popis aktivnih tvari koje treba ocijeniti radi njihova mogućeg uvrštavanja u priloge I., I.A ili I.B Direktivi 98/8/EZ Europskog parlamenta i Vijeća [3].
That list includes etofenprox.
Na tom se popisu nalazi i etofenproks.
Etofenprox has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 18, insecticides, acaricides and products to control other arthropods, as defined in Annex V to that Directive, which corresponds to product-type 18 as defined in Annex V to Regulation (EU) No 528/2012.
Etofenproks je ocijenjen u skladu s člankom 11. stavkom 2. Direktive 98/8/EZ za uporabu u vrsti proizvoda 18, insekticidi, akaricidi i proizvodi za suzbijanje drugih člankonožaca kako su definirani u Prilogu V. toj Direktivi, što odgovara vrsti proizvoda 18 prema definiciji iz Priloga V. Uredbi (EU) br. 528/2012.
Austria was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 9 August 2011 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.
Austrija je imenovana državom članicom izvjestiteljicom te je 9. kolovoza 2011. u skladu s člankom 14. stavcima 4. i 6. Uredbe (EZ) br. 1451/2007 Komisiji podnijela izvješće nadležnog tijela zajedno s preporukom.
In accordance with Article 15(4) of Regulation (EC) No 1451/2007, the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 27 September 2013, in an assessment report.
U skladu s člankom 15. stavkom 4. Uredbe (EZ) br. 1451/2007, nalazi te revizije uvršteni su 27. rujna 2013. u izvješće o ocjeni u okviru Stalnog odbora za biocidne proizvode.
It appears from that report that biocidal products used for product-type 18 and containing etofenprox may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC.
Izvješće je pokazalo da se može očekivati da će biocidni pripravci koji se koriste u vrsti proizvoda 18 i sadržavaju etofenproks zadovoljiti zahtjeve predviđene člankom 5. Direktive 98/8/EZ.
It also appears from the reports that the characteristics of etofenprox render it liable to bioaccumulate (B) and toxic (T), in accordance with the criteria laid down in Annex XIII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council [4].
Izvješće je pokazalo i da je etofenproks zbog svojih svojstava potencijalno bioakumulativan (B) i toksičan (T), u skladu s kriterijima propisanim Prilogom XIII. Uredbi (EZ) br. 1907/2006 Europskog parlamenta i Vijeća [4].
The period of approval should be 10 years in consistency with the current practice under Directive 98/8/EC, since the conditions of Article 90(2) of Regulation (EU) No 528/2012 are not met.
Odobrenje bi se trebalo odnositi na razdoblje od 10 godina u skladu s postojećom praksom na temelju Direktive 98/8/EZ, s obzirom na to da uvjeti iz članka 90. stavka 2. Uredbe (EU) br. 528/2012 nisu zadovoljeni.
However, for the purpose of authorising products in accordance with Article 23 of Regulation (EU) No 528/2012, etofenprox shall be considered as a candidate for substitution pursuant to Article 10(1)(d) of that Regulation.
Međutim, za potrebe odobrenja proizvoda u skladu s člankom 23. Uredbe (EU) br. 528/2012, etofenproks se smatra potencijalnom tvari za zamjenu u skladu s člankom 10. stavkom 1. točkom (d) te Uredbe.
It is therefore appropriate to approve etofenprox for use in biocidal products for product-type 18.
Stoga je primjereno odobriti uporabu etofenproksa u biocidnim pripravcima za vrstu proizvoda 18.
Since the evaluation did not address nanomaterials, the approval should not cover such materials pursuant to Article 4(4) of Regulation (EU) No 528/2012.
S obzirom da se ocjena nije odnosila na nanomaterijale, na temelju članka 4. stavka 4. Uredbe (EU) br. 528/2012 odobrenje ne bi trebalo obuhvaćati takve materijale.
Etofenprox shall be approved as an active substance for use in biocidal products for product-type 18, subject to the specifications and conditions set out in the Annex.
Etofenproks se odobrava kao aktivna tvar za uporabu u biocidnim pripravcima za vrstu proizvoda 18, podložno specifikacijama i uvjetima iz Priloga.
Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).
Uredba (EZ) br. 1907/2006 Europskog parlamenta i Vijeća od 18. prosinca 2006. o registraciji, evaluaciji, autorizaciji i ograničavanju kemikalija (REACH) i osnivanju Europske agencije za kemikalije te o izmjeni Direktive 1999/45/EZ i stavljanju izvan snage Uredbe Vijeća (EEZ) br. 793/93 i Uredbe Komisije (EZ) br. 1488/94 kao i Direktive Vijeća 76/769/EEZ i direktiva Komisije 91/155/EEZ, 93/67/EEZ, 93/105/EZ i 2000/21/EZ (SL L 396, 30.12.2006., str 1.).
EC No: 407-980-2
EZ br.: 407-980-2
CAS No: 80844-07-1
CAS br.: 80844-07-1
Etofenprox is considered a candidate for substitution in accordance with article 10(1)(d) of Regulation (EU) No 528/2012.
Etofenproks se smatra potencijalnom tvari za zamjenu u skladu s člankom 10. stavkom 1. točkom (d) Uredbe (EU) br. 528/2012.
The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.
Pri ocjenjivanju proizvoda posebna se pozornost posvećuje izloženosti, rizicima i učinkovitosti povezanima sa svakom uporabom na koju se odnosi zahtjev za odobrenje, a koja nije proučena u okviru procjene rizika aktivne tvari na razini Unije.
For products that may lead to residues in food or feed, the need to set new or to amend existing maximum residue levels (MRLs) in accordance with Regulation (EC) No 470/2009 of the European Parliament and of the Council [3] or Regulation (EC) No 396/2005 of the European Parliament and of the Council [4] shall be verified, and any appropriate risk mitigation measures shall be taken to ensure that the applicable MRLs are not exceeded.
Za proizvode koji mogu ostaviti ostatke u hrani ili hrani za životinje treba provjeriti je li potrebno odrediti nove ili izmijeniti postojeće maksimalne razine ostataka (MRL-ove) u skladu s Uredbom (EZ) br. 470/2009 Europskog parlamenta i Vijeća [3] ili Uredbom (EZ) br. 396/2005 Europskog parlamenta i Vijeća [4] i poduzeti sve odgovarajuće mjere za smanjenje rizika kako bi se osiguralo da se ne prekorače primjenjivi MRL-ovi.
For the implementation of the common principles of Annex VI to Regulation (EU) No 528/2012, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm
Za provedbu općih načela Priloga VI. Uredbi (EU) br. 528/2012, sadržaj i zaključci izvješća o ocjeni nalaze se na web-mjestu Komisije: http://ec.europa.eu/comm/environment/biocides/index.htm.
Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council (OJ L 152, 16.6.2009, p. 11).
Uredba (EZ) br. 470/2009 Europskog parlamenta i Vijeća od 6. svibnja 2009. o propisivanju postupka Zajednice za određivanje najvećih dopuštenih količina ostataka farmakološki djelatnih tvari u hrani životinjskoga podrijetla, o stavljanju izvan snage Uredbe Vijeća (EEZ) br. 2377/90 i o izmjeni Direktive 2001/82/EZ Europskog parlamenta i Vijeća i Uredbe (EZ) br. 726/2004 Europskog parlamenta i Vijeća (SL L 152, 16.6.2009., str. 11.).
Commission Implementing Regulation (EU) No 1037/2013
Provedbena uredba Komisije (EU) br. 1037/2013
approving IPBC as an existing active substance for use in biocidal products for product-type 6
o odobrenju IPBC-a kao postojeće aktivne tvari za uporabu u biocidnim proizvodima za vrstu proizvoda 6
Commission Regulation (EC) No 1451/2007 [2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council [3].
Uredbom Komisije (EZ) br. 1451/2007 [2] utvrđen je popis aktivnih tvari koje treba ocijeniti radi njihovog mogućeg uvrštenja u Prilog I., I. A ili I. B Direktivi 98/8/EZ Europskog parlamenta i Vijeća [3].
That list includes IPBC.
Na tom se popisu nalazi i IPBC.
IPBC has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 6, in-can preservatives, as defined in Annex V to that Directive, which corresponds to product-type 6 as defined in Annex V to Regulation (EU) No 528/2012.
IPBC je ocijenjen u skladu s člankom 11. stavkom 2. Direktive 98/8/EZ za uporabu u vrsti proizvoda 6, konzervansima za gotove proizvode, kako su definirani u Prilogu V. toj Direktivi, što odgovara vrsti proizvoda 6 prema definiciji iz Priloga V. Uredbi (EU) br. 528/2012.
Denmark was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 27 June 2011 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.
Danska je imenovana državom članicom izvjestiteljicom te je 27. lipnja 2011. u skladu s člankom 14. stavcima 4. i 6. Uredbe (EZ) br. 1451/2007 Komisiji podnijela izvješće nadležnog tijela zajedno s preporukom.
It appears from that report that biocidal products used for product-type 6 and containing IPBC may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC.
Prema tom izvješću može se očekivati da će biocidni proizvodi koji se koriste kao proizvodi vrste 6 i sadrže IPBC zadovoljiti uvjete propisane člankom 5. Direktive 98/8/EZ.
It is therefore appropriate to approve IPBC for use in biocidal products for product-type 6.
Stoga je primjereno odobriti uporabu IPBC-a u biocidnim proizvodima za vrstu proizvoda 6.
IPBC shall be approved as an active substance for use in biocidal products for product-type 6, subject to the specifications and conditions set out in the Annex.
IPBC se odobrava kao aktivna tvar za uporabu u biocidnim proizvodima za vrstu proizvoda 6, podložno specifikacijama i uvjetima iz Priloga.
odo-2-propynyl butylcarbamate
odo-2-propinil butilkarbamat
EC No: 259-627-5
EZ br.: 259-627-5
CAS No: 55406-53-6
CAS br.: 55406-53-6
Where exposure cannot be reduced to an acceptable level by other means, products shall be used with appropriate personal protective equipment.
Proizvodi se trebaju koristiti uz odgovarajuću osobnu zaštitnu opremu u slučajevima kada se izloženost ne može na drugi način smanjiti na prihvatljivu razinu.
Where a treated article has been treated with or intentionally incorporates IPBC, and where necessary due to the possibility of skin contact as well as the release of IPBC under normal conditions of use, the person responsible for placing the treated article on the market shall ensure that the label provides information on the risk of skin sensitisation, as well as the information referred to in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012.
U slučaju da je neki tretirani proizvod tretiran IPBC-om ili nenamjerno sadržava IPBC i, prema potrebi, zbog mogućnosti da će doći do kontakta s kožom i ispuštanja IPBC-a u okoliš u uobičajenim uvjetima korištenja, osoba odgovorna za stavljanje tretiranog proizvoda na tržište osigurava da su na deklaraciji navedeni podaci o riziku preosjetljivosti kože te podaci iz drugog podstavka članka 58. stavka 3. Uredbe (EU) br. 528/2012.
Commission Implementing Regulation (EU) No 1038/2013
Provedbena uredba Komisije (EU) br. 1038/2013
approving tebuconazole as an existing active substance for use in biocidal products for product-types 7 and 10
o odobrenju tebukonazola kao postojeće aktivne tvari za uporabu u biocidnim pripravcima za vrste proizvoda 7 i 10
Commission Regulation (EC) No 1451/2007 [2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council [3].
Uredbom Komisije (EZ) br. 1451/2007 [2] utvrđen je popis aktivnih tvari koje treba ocijeniti radi njihovog mogućeg uvrštavanja u Prilog I., IA ili IB Direktivi 98/8/EZ. Europskog parlamenta i Vijeća [3].
That list includes tebuconazole.
Popis uključuje tebukonazol.
Tebuconazole has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 7, film preservatives, and product-type 10, masonry preservatives, as defined in Annex V to that Directive, which correspond respectively to product-types 7 and 10 as defined in Annex V to Regulation (EU) No 528/2012.
Tebukonazol je ocijenjen u skladu s člankom 11. stavkom 2. Direktive 98/8/EZ za uporabu u vrsti proizvoda 7, sredstvima za zaštitu površine i vrsti proizvoda 10, sredstvima za zaštitu u graditeljstvu, kako je određeno u Prilogu V. toj Direktivi, što odgovara vrstama proizvoda 7 i 10 kako je utvrđeno u Prilogu V. Uredbi (EU) br. 528/2012.
Denmark was designated as rapporteur Member State and submitted the competent authority reports, together with recommendations, to the Commission on 16 April 2012 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.
Danska je imenovana državom članicom izvjestiteljicom i dostavila je Komisiji 16. travnja 2012. izvješća nadležnog tijela uz preporuke u skladu s člankom 14. stavcima 4. i 6. Uredbe (EZ) br. 1451/2007.
The competent authority reports were reviewed by the Member States and the Commission.
Države članice i Komisija pregledale su izvješća nadležnog tijela.
It appears from those reports that biocidal products used for product-types 7 and 10 and containing tebuconazole may be expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC.
Na temelju tih izvješća može se očekivati da biocidni pripravci koji se koriste u vrstama proizvoda 7 i 10 i koji sadrže tebukonazol zadovolje uvjete utvrđene u članku 5. Direktive 98/8/EZ.
It also appears from the reports that the characteristics of tebuconazole render it very persistent (vP) and toxic (T) in accordance with the criteria laid down in Annex XIII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council [4].
Iz izvješća također proizlazi da njegove značajke tebukonazol čine vrlo postojanim (vP) i toksičnim (T) u skladu s kriterijima koji su navedeni u Prilogu XIII. Uredbi (EZ) br. 1907/2006 Europskog parlamenta i Vijeća [4].
The period of approval should be 10 years in consistency with the current practice under Directive 98/8/EC, since the conditions of Article 90(2) of Regulation (EU) No 528/2012 are not met.
Razdoblje odobrenja trebalo bi biti 10 godina u skladu s trenutnom praksom u okviru Direktive 98/8/EZ budući da uvjeti iz članka 90. stavka 2. Uredbe (EU) br. 528/2012 nisu ispunjeni.
However, for the purpose of authorising products in accordance with Article 23 of Regulation (EU) No 528/2012, tebuconazole shall be considered as a candidate for substitution pursuant to Article 10(1)(d) of that Regulation.
Međutim u svrhu odobrenja proizvoda u skladu s člankom 23. Uredbe (EU) br. 528/2012 tebukonazol se treba smatrati kandidatom za zamjenu u skladu s člankom 10. stavkom 1. točkom (d) te Uredbe.
It is therefore appropriate to approve tebuconazole for use in biocidal products for product-types 7 and 10.
Stoga je prikladno odobriti uporabu tebukonazola u biocidnim pripravcima za vrste proizvoda 7 i 10.
Tebuconazole shall be approved as an active substance for use in biocidal products for product-types 7 and 10, subject to the specifications and conditions set out in the Annex.
Tebukonazol se odobrava kao aktivna tvar za uporabu u biocidnim pripravcima za vrste proizvoda 7 i 10, podložno specifikacijama i uvjetima koji su navedeni u Prilogu ovoj Uredbi.
Tebuconazole
Tebukonazol
1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol
1 - (4-klorofenil) -4,4-dimetil-3-(1,2,4-triazol-1-ilmetil) pentan-3-ol
EC No: 403-640-2
EZ br.: 403-640-2
CAS No: 107534-96-3
CAS br.: 107534-96-3
Tebuconazole is considered a candidate for substitution in accordance with Article 10(1)(d) of Regulation (EU) No 528/2012.
Tebukonazol se smatra kandidatom za zamjenu u skladu s člankom 10. stavkom 1. točkom (d) Uredbe (EU) br. 528/2012.
The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.
Procjena proizvoda će se posebno usmjeriti na izloženost, rizike i djelotvornost koji su vezani uz sve uporabe koje su obuhvaćene zahtjevom za izdavanje odobrenja, ali nisu obrađeni u procjeni rizika na razini Unije za aktivnu tvar.
For industrial users, safe operational procedures and appropriate organisational measures shall be established.
Za industrijske je korisnike potrebno odrediti sigurne radne postupke i odgovarajuće organizacijske mjere.
In the view of the risk for the soil compartment, tebuconazole shall not be used in a sealant that will be used to seal vertical joints outside residential facades (e.g. between two houses), unless it can be demonstrated in the application for product authorisation that risks can be reduced to an acceptable level by other means.
Vezano uz rizik za segment tla, tebukonazol se ne smije koristiti za obradu brtvila koje će se koristiti za brtvljenje punila okomitih spojeva izvan fasada stambenih građevina (npr. između dvije kuće), osim ako se u zahtjevu za odobrenje proizvoda može dokazati da se rizici mogu smanjiti na prihvatljivu razinu na drugi način.
For the implementation of the common principles of Annex VI to Regulation (EU) No 528/2012, the content and conclusions of assessment reports are available on the Commission website: http://ec.europa.eu/comm/environment/biocides/index.htm
Za primjenu jedinstvenih načela Priloga VI.
Commission Implementing Regulation (EU) No 1039/2013
Provedbena uredba Komisije (EU) br. 1039/2013
modifying the approval of nonanoic acid as an existing active substance for use in biocidal products for product-type 2
o odobrenju nonanske kiseline kao postojeće aktivne tvari za uporabu u biocidnim proizvodima za vrstu proizvoda 2
Commission Regulation (EC) No 1451/2007 [2] establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council [3].
Uredbom Komisije (EZ) br. 1451/2007 [2] utvrđen je popis aktivnih tvari koje treba ocijeniti radi njihovog mogućeg uvrštavanja u Prilog I., I.A ili I.B Direktivi 98/8/EZ Europskog parlamenta i Vijeća [3].
That list includes nonanoic acid.
Na tom se popisu nalazi i nonanska kiselina.
Nonanoic acid has been included into Annex I to Directive 98/8/EC for use in product-type 2 through Commission Directive 2012/41/EU [4], and is therefore considered as approved for that product-type by virtue of Article 86 of Regulation (EU) No 528/2012.
Nonanska kiselina je Direktivom Komisije 2012/41/EU [4] uvrštena u Prilog I. Direktivi 98/8/EZ za uporabu u vrsti proizvoda 2 i stoga se smatra odobrenom za tu vrstu proizvoda na temelju članka 86. Uredbe (EU) br. 528/2012.
Furthermore, nonanoic acid has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product-type 10, masonry preservatives, as defined in Annex V to that Directive.
Nadalje, nonanska kiselina je ocijenjena u skladu s člankom 11. stavkom 2. Direktive 98/8/EZ za uporabu u vrsti proizvoda 10, sredstvima za zaštitu zidarskih proizvoda, kako su definirana u Prilogu V. toj Direktivi.
The evaluation covered use as an algaecide for the curative treatment of construction materials.
Ocjena je obuhvaćala uporabu kao algicid koji se koristi za zaštitu građevinskih materijala.
That specific use is now covered by product-type 2 as defined in Annex V to Regulation (EU) No 528/2012.
Za tu specifičnu uporabu sada služe proizvodi vrste 2, kako je utvrđeno u Prilogu V. Uredbi (EU) br. 528/2012.
Austria was designated as Rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 3 April 2012 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007.
Austrija je imenovana državom članicom izvjestiteljicom te je 3. travnja 2012. u skladu s člankom 14. stavcima 4. i 6. Uredbe (EZ) br. 1451/2007 Komisiji podnijela izvješće nadležnog tijela zajedno s preporukom.